```

[Federal Register Volume 89, Number 245 (Friday, December 20, 2024)]
[Notices]
[Pages 104208-104209]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30403]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on October 3, 2024, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, Biointelect Pty, Ltd., Sydney, AUSTRALIA; SPI Pharma, 
Inc.,

[[Page 104209]]

Wilmington, DE; Serimmune, Goleta, CA; UNITED KINGDOM HEALTH SECURITY 
AGENCY (UKHSA), Salisbury, UNITED KINGDOM; University of Connecticut, 
Farmington, CT; VGXI, Inc., Conroe, TX; ABSS Solutions, Inc., Upper 
Marlboro, MD; BiosYnth SRL, Milan, ITALY; Idevax, Wijnegem, BELGIUM; 
IntegerBio, Inc., Gaithersburg, MD; Phoreus Biotechnology, Inc., 
Olathe, KS; PrecNA, LLC, North Potomac, MD; Sepragen Corp., Union City, 
CA; Trellis Bioscience, Inc., Redwood City, CA; AB Validation, Inc., 
Quebec, CANADA; AuraVax Therapeutics, Inc., Houston, TX; CuriRx, Inc., 
Wilmington, MA; IMA Evaluations, LLC, dba IMA Clinical Research, 
Tarrytown, NY; MustardSeed PMO, West Chester, PA; Symbiosis.io, LLC, 
Smyrna, GA; Tornado Therapeutics, Boston, MA; Amneal Pharmaceuticals of 
New York, LLC, Brookhaven, NY; Blue Spark Technologies, Inc., Westlake, 
OH; Inhalon Biopharma, Inc., Morrisville, NC; Intelligene, Inc., 
Taipei, TAIWAN; Rocket Science Health US Corp., Seattle, WA; Rutgers, 
The State University of New Jersey, Piscataway, NJ; The Administrators 
of the Tulane Educational Fund, New Orleans, LA; Verisim Life, Inc., 
San Francisco, CA; Arcturus Therapeutics Holdings, Inc., San Diego, CA; 
Blu Zone Bioscience & Supply Chain Solutions, LLC, Frederick, MD; 
Elligo Health Research, Inc., Austin, TX; Guide Biomedical Solutions, 
LLC, Media, PA; Integral Molecular, Philadelphia, PA; Komo Biosciences, 
Inc., Newton, MA; P95, BV, Leuven, BELGIUM; Southwest Research 
Institute, San Antonio, TX; Statistics & Data Corp., Tempe, AZ; Stoic 
Bio, Inc., San Diego, CA; Valaria Technical Consultants, LLC, 
Westminster, MD; Vaxine Pty, Ltd., Marion, AUSTRALIA; Zeteo Biomedical, 
LLC, Austin, TX; Concept to Market, LLC, Monrovia, MD; DSBio 
Consulting, LLC, Annapolis, MD; Deimos Biosciences, San Francisco, CA; 
GMED North America, Inc., Rockville, MD; InvisiShield Technologies, 
Ltd., Emeryville, CA; MigVax, Ltd., Kiryat Shmona, ISRAEL; Polaris 
Alpha Advanced Systems, Inc., Fredericksburg, VA; Pop Test Oncology, 
LLC, Cliffside Park, NJ; Sapphiros, Boston, MA; Articulate Labs, Inc., 
Dallas, TX; Empatica, Inc., Cambridge, MA; LifeMine Therapeutics, Inc., 
Cambridge, MA; Luminous Therapeutics Corp., Columbia, MD; Nabla Bio, 
Inc., Cambridge, MA; Qoolabs, Inc., Carlsbad, CA; Rapid Novor, Inc., 
Kitchener, CANADA; Scorpius BioManufacturing, San Antonio, TX; 
Sunflower Therapeutics PBC, Medford, MA; GreenRoads Diagnostics, Inc., 
San Diego, CA; Logical Images, dba ``VisualDx'', Rochester, NY; Mirai 
Biosciences, Cambridge, MA; The Scripps Research Institute, La Jolla, 
CA; AmplifyBio, LLC, West Jefferson, OH; Andelyn Biosciences, Inc., 
Columbus, OH; Binary Pharmaceuticals, LLC, Hot Springs, AR; BioCina 
PTY, Ltd., West Torrens, AUSTRALIA; Cypress Biologics, LLC, Portland, 
OR; Fermeate, Inc., San Francisco, CA; HMH Hospitals Corp, dba CDI, 
Nutley, NJ; Meso Scale Diagnostics, LLC, Rockville, MD; Systems & 
Technology Research, LLC, Woburn, MA; Telesis Bio, San Diego, CA; 
Thermo Fisher, South San Francisco, CA; University of Massachusetts 
Lowell, Lowell, MA; ViQi, Inc., Santa Barbara, CA; DemeTech Corp., 
Miami, FL; INFEX Therapeutics, Alderley Edge, UNITED KINGDOM; Mercury 
Bio, Inc., Santa Fe, NM; Phageolytix, Inc., Jacksonville, FL; Phenom 
Pharmaceuticals, LLC, Miami Beach, FL; RIBOPRO BV, Oss, NETHERLANDS; 
RNhale GmbH, Munich, GERMANY; The University of Chicago Medicine, 
Chicago, IL; Bioblue CMC/Manufacturing Consulting, LLC, San Diego, CA; 
Oligo Foundry, Inc., San Diego, CA; PNUVAX, Inc., Wilmington, DE; 
Prosoft Software, Inc., dba Prosoft Clinical, Chesterbrook, PA; Simon 
Williams Pharma Consulting (SWPC), LLC, Gibbsboro, NJ; Dillico, Meylan, 
FRANCE; INFINIFLUIDICS, Philadelphia, PA; Primrose Bio, Inc., San 
Diego, CA; SIMETRI, Inc., Winter Park, FL; The Trustees of the 
University of Pennsylvania, Philadelphia, PA; and WCG, Princeton, NJ, 
have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and RRPV intends to file additional 
written notifications disclosing all changes in membership.
    On January 5, 2024, RRPV filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to section 6(b) of the Act on 
April 16, 2024 (89 FR 26928).
    The last notification was filed with the Department on July 11, 
2024. The Department of Justice published a notice in the Federal 
Register pursuant to section 6(b) of the Act on October 11, 2024 (89 FR 
82631).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-30403 Filed 12-19-24; 8:45 am]
BILLING CODE P
```